EGFR and non-small cell lung carcinoma: In 2021, FDA approval was granted to mobocertinib for adult patients with locally advanced or metastatic NSCLC featuring EGFR exon 20 insertion mutations, identified through an FDA-sanctioned test, whose condition has advanced following platinum-based chemotherapy [124].